Baidu on Wednesday reported second quarter revenue of 32.71 billion yuan ($4.56 billion), just below street estimates of 32.92 billion yuan. The print also fell from revenue of 33.93 billion yuan a ...

Investing.com -- Walmart Inc. reported mixed second-quarter results on Thursday, with revenue exceeding expectations but earnings falling short of analyst estimates. The retail giant also raised its ...

Seasonally-adjusted U.S. jobless claims climbed to 235,000 in the week ended on August 16, up from 224,000 in the prior week. Economists had predicted a reading of 226,000. The four-week moving ...

The preliminary S&P Global (NYSE: SPGI) UK Composite Purchasing Managers’ Index rose to 53.0, its highest level since August 2024 and a significant improvement from July’s final reading of 51.5. The ...

Investing.com -- China Petroleum (OTC: SNPTY) & Chemical Corp., known as Sinopec (OTC: SHIIY ), reported a 40% decline in net profit for the first half of 2025, as lower oil prices weighed on the ...

Investing.com -- Barclays (LON: BARC) has raised its forecast for euro area inflation in 2025, now expecting headline consumer prices to average 2.1% compared with the 2% projection it published in ...

Investing.com -- The European Union-United States trade deal does not currently include the wine and spirits sector, European Union Trade Commissioner Maros Sefcovic said on Thursday. Sefcovic noted ...

In an update to its U.S. e-commerce model, JPMorgan said U.S. online sales rose 5.3% year over year in the second quarter, broadly stable with the 5.6% growth seen in the first quarter. “U.S.

Investing.com -- Israel has given final approval to a project that will expand settlements in the West Bank, a move critics say undermines prospects for Palestinian statehood.

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Investing.com -- Morgan Stanley (NYSE: MS) has initiated coverage of Trevi Therapeutics (NASDAQ: TRVI) with an “overweight” rating and a price target of $18. The brokerage flags Trevi’s development of ...

The joint statement noted that the U.S. agreed to apply only pre-existing Most Favored Nation (MFN) tariffs of below 15% from September 1 on EU aircraft and parts, generic pharmaceuticals and ...